On May 5, 2020, ASLAN Pharmaceuticals Limited and Mark McHale, the Company's Chief Development Officer, mutually agreed that Dr. McHale will step down from the Company effective May 31, 2020, and return to the UK for personal reasons. Dr. McHale will continue in his role through May 31, 2020 and will then serve as an advisor to the Company for the ASLAN004 program. The company announced the appointment of Alison Ward as Chief Development Officer.